Markets:

Overview

News

Currencies

International

Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Stocks That Hit 52-Week Lows On Monday ↗

February 28, 2022

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...

Via Benzinga

Recap: Reata Pharmaceuticals Q4 Earnings ↗

February 28, 2022

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

FDA Strikes Off Reata Pharma's Bardoxolone Application For Rare Kidney Disease ↗

February 28, 2022

The FDA has issued a Complete Response Letter (CRL) regarding Reata Pharmaceuticals Inc's (NASDAQ: RETA) application seeking approval for bardoxolone...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗

February 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

3 Stocks Insiders Are Buying ↗

January 05, 2022

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

45 Biggest Movers From Yesterday ↗

January 05, 2022

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 04, 2022

Gainers Hoth Therapeutics (NASDAQ:

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

January 04, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women...

Via Benzinga

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗

December 12, 2021

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet ↗

December 09, 2021

Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20. The U.S. has...

Via Benzinga

Topics Stocks

56 Biggest Movers From Yesterday ↗

December 10, 2021

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement...

Via Benzinga

Looking At Reata Pharmaceuticals's Recent Whale Trades ↗

December 09, 2021

Someone with a lot of money to spend has taken a bearish stance on Reata Pharmaceuticals (NASDAQ:RETA). And retail traders should know. We noticed this today when the big position...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 09, 2021

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 88.08% to $5.61 during Thursday's regular session. As of 12:30 EST, Ensysce Biosciences's stock is...

Via Benzinga

Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher ↗

December 09, 2021

Midway through trading Thursday, the Dow traded down 0.18% to 35,691.63 while the NASDAQ fell 0.72% to 15,672.75. The S&P also fell, dropping 0.37% to 4,683.86. The U.S. has...

Via Benzinga

Topics Stocks

38 Stocks Moving In Thursday's Mid-Day Session ↗

December 09, 2021

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 92.9% to $5.19 after the company signed an exclusive summary distribution agreement with Innovimed Sp...

Via Benzinga

Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday ↗

December 09, 2021

The biopharmaceutical company got some potentially devastating news from regulators.

Via The Motley Fool

Reata Pharmaceuticals Stock Nosedives On FDA Panel's Rejection Of Kidney Drug ↗

December 09, 2021

The vote was unanimous. Advisors said the evidence doesn't support the drug's merits.

Via Investor's Business Daily

What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals ↗

December 09, 2021

Over the past 3 months, 5 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗

December 09, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low ↗

December 09, 2021

Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S...

Via Benzinga

Topics Stocks

Why Are Reata Pharmaceuticals Shares Plunging Premarket? ↗

December 09, 2021

The FDA's Cardiovascular and Renal Drugs Advisory Committee voted that the agency should not approve Reata Pharmaceuticals Inc's (NASDAQ: RETA) bardoxolone...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 09, 2021

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 09, 2021

Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday!

Via InvestorPlace

21 Stocks Moving in Thursday's Pre-Market Session ↗

December 09, 2021

Gainers Pear Therapeutics, Inc. (NASDAQ: PEAR) rose 64% to $15.20 in pre-market trading after climbing around 16% on Wednesday. Ensysce Biosciences, Inc. (NASDAQ: ENSC) rose 32.2...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today